AR111346A1 - Compuesto peptídico con acción activante sobre receptores gip - Google Patents
Compuesto peptídico con acción activante sobre receptores gipInfo
- Publication number
- AR111346A1 AR111346A1 ARP180100762A ARP180100762A AR111346A1 AR 111346 A1 AR111346 A1 AR 111346A1 AR P180100762 A ARP180100762 A AR P180100762A AR P180100762 A ARP180100762 A AR P180100762A AR 111346 A1 AR111346 A1 AR 111346A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptide compound
- activating action
- gip receptors
- medicament
- peptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017072556 | 2017-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111346A1 true AR111346A1 (es) | 2019-07-03 |
Family
ID=62089992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100762A AR111346A1 (es) | 2017-03-31 | 2018-03-28 | Compuesto peptídico con acción activante sobre receptores gip |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10435445B2 (enExample) |
| EP (1) | EP3601329B1 (enExample) |
| JP (2) | JP7175912B2 (enExample) |
| KR (1) | KR102778100B1 (enExample) |
| CN (1) | CN110709414B (enExample) |
| AR (1) | AR111346A1 (enExample) |
| AU (2) | AU2018246553B2 (enExample) |
| BR (1) | BR112019020438A2 (enExample) |
| CA (1) | CA3058361A1 (enExample) |
| CL (1) | CL2019002790A1 (enExample) |
| CO (1) | CO2019012271A2 (enExample) |
| EA (1) | EA201992327A1 (enExample) |
| EC (1) | ECSP19078239A (enExample) |
| IL (1) | IL269581B2 (enExample) |
| JO (2) | JOP20190211A1 (enExample) |
| MA (1) | MA48998A (enExample) |
| MY (1) | MY205279A (enExample) |
| PE (1) | PE20200675A1 (enExample) |
| PH (1) | PH12019502252A1 (enExample) |
| SG (1) | SG11201908542QA (enExample) |
| TW (1) | TWI801373B (enExample) |
| WO (1) | WO2018181864A1 (enExample) |
| ZA (1) | ZA201906171B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3856768A2 (en) * | 2018-09-24 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
| US20220016215A1 (en) * | 2018-09-24 | 2022-01-20 | Takeda Phaarmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
| AR119471A1 (es) | 2019-08-01 | 2021-12-22 | Lilly Co Eli | Compuestos agonistas de gipr |
| WO2021175974A1 (en) | 2020-03-06 | 2021-09-10 | Sanofi | Peptides as selective gip receptor agonists |
| IL296592A (en) * | 2020-03-25 | 2022-11-01 | Takeda Pharmaceuticals Co | Qd dosing of gip receptor agonist peptide compounds and uses thereof |
| IL296219A (en) * | 2020-03-25 | 2022-11-01 | Takeda Pharmaceuticals Co | Qw dosing of gip receptor agonist peptide compounds and uses thereof |
| EP4171662A1 (en) | 2020-03-31 | 2023-05-03 | Antaros Medical AB | Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposes |
| AU2021312323A1 (en) | 2020-07-22 | 2023-02-02 | Novo Nordisk A/S | Co-agonists at GLP-1 and GIP receptors suitable for oral delivery |
| CN117866050A (zh) * | 2021-05-28 | 2024-04-12 | 广东众生睿创生物科技有限公司 | 多肽的制备及其应用 |
| WO2023031455A1 (en) | 2021-09-06 | 2023-03-09 | Sanofi Sa | New peptides as potent and selective gip receptor agonists |
| EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4433093A1 (en) | 2021-11-15 | 2024-09-25 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| CN116891522B (zh) * | 2022-04-01 | 2024-05-14 | 南京知和医药科技有限公司 | 一种长效胰高血糖素样肽-1衍生物及其制备方法和用途 |
| JP7886963B2 (ja) * | 2022-04-07 | 2026-07-08 | 広東衆生睿創生物科技有限公司 | 糖尿病、肥満症およびその関連疾患を治療および／または予防するための医薬品の調製における、ポリペプチドの医薬的使用 |
| EP4299052A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and a permeation enhancer |
| EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
| CN117756913B (zh) * | 2022-11-07 | 2025-05-09 | 内蒙古博睿精创科技有限公司 | 一种新型长效多肽化合物、组合物及其应用 |
| WO2024209050A1 (en) | 2023-04-05 | 2024-10-10 | Antag Therapeutics Aps | Gip activity modulators and orthostatic intolerance |
| AR134436A1 (es) * | 2023-11-22 | 2026-01-14 | Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd | Uso de un agonista dual glp-1r / gipr en la fabricación de un medicamento veterinario |
| WO2025154021A1 (en) * | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Improved gip receptor agonist peptide compounds and uses thereof |
| WO2025154020A1 (en) * | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Improved gip receptor agonist peptide compounds and uses thereof |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04145099A (ja) | 1990-10-05 | 1992-05-19 | Sanwa Kagaku Kenkyusho Co Ltd | Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途 |
| CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
| GB0404124D0 (en) | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
| PT1180121E (pt) | 1999-05-17 | 2004-03-31 | Conjuchem Inc | Peptidos insulinotropicos de longa duracao |
| EP1302462A4 (en) | 2000-07-17 | 2007-07-18 | Takeda Pharmaceutical | SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF |
| US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
| BR0315815A (pt) | 2002-11-01 | 2005-09-13 | Takeda Pharmaceutical | Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto |
| AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
| US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| EP1669352A4 (en) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | THIAZOLINE DERIVATIVE AND ITS USE |
| WO2005058823A1 (ja) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | ウレア誘導体、その製造法及び用途 |
| US7456218B2 (en) | 2003-12-25 | 2008-11-25 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
| WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
| WO2005087710A1 (ja) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | アミノフェニルプロパン酸誘導体 |
| JP4859665B2 (ja) | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| CA2597649A1 (en) | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| US8957070B2 (en) | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
| WO2006121904A1 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use |
| US20090054435A1 (en) | 2005-07-29 | 2009-02-26 | Hiroshi Imoto | Phenoxyalkanoic Acid Compound |
| EP1916234B1 (en) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| JP4094660B1 (ja) | 2005-08-10 | 2008-06-04 | 武田薬品工業株式会社 | 糖尿病治療剤 |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| US20090170762A1 (en) | 2005-09-08 | 2009-07-02 | Uutech Limited | Treatment of Diabetes Related Obesity |
| EP1937716A2 (en) | 2005-09-08 | 2008-07-02 | Uutech Limited | Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function |
| AU2007227202B2 (en) | 2006-03-21 | 2013-08-22 | Amylin Pharmaceuticals, Llc | Peptide-peptidase inhibitor conjugates and methods of using same |
| AU2007265966B2 (en) | 2006-06-27 | 2012-05-17 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
| US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| JP5399244B2 (ja) | 2006-08-17 | 2014-01-29 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | 選択可能な特性を持つｄｐｐ−ｉｖ耐性ｇｉｐハイブリッドポリペプチド |
| EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| CN101573357B (zh) | 2006-10-19 | 2013-01-23 | 武田药品工业株式会社 | 吲哚化合物 |
| WO2008093639A1 (ja) | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| AU2008215490A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of PPAR-gamma |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| EP2157859A4 (en) | 2007-06-19 | 2011-01-12 | Takeda Pharmaceutical | INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE |
| US8598314B2 (en) | 2007-09-27 | 2013-12-03 | Amylin Pharmaceuticals, Llc | Peptide-peptidase-inhibitor conjugates and methods of making and using same |
| ES2558842T3 (es) | 2008-06-17 | 2016-02-09 | Indiana University Research And Technology Corporation | Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad |
| KR20130133103A (ko) | 2008-08-07 | 2013-12-05 | 입센 파마 에스.에이.에스 | Ｎ-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(ｇｉｐ)의 유사체 |
| CA2732949C (en) | 2008-08-07 | 2016-12-20 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide |
| CA2733005C (en) | 2008-08-07 | 2016-09-27 | Ipsen Pharma S.A.S. | Truncated analogues of glucose-dependent insulinotropic polypeptide |
| ES2574835T3 (es) | 2008-08-07 | 2016-06-22 | Ipsen Pharma S.A.S. | Análogos del polipéptido insulinotrópico dependiente de glucosa |
| EP2376097A4 (en) | 2008-12-19 | 2012-10-03 | Univ Indiana Res & Tech Corp | PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY |
| WO2010148089A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| WO2011014680A2 (en) | 2009-07-31 | 2011-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Gastric inhibitory peptide variants and their uses |
| KR20120123443A (ko) | 2010-01-27 | 2012-11-08 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트 |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
| RU2013133803A (ru) | 2010-12-22 | 2015-01-27 | Маркадиа Байотек, Инк. | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп |
| NZ612297A (en) | 2010-12-22 | 2015-10-30 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting gip receptor activity |
| KR102002783B1 (ko) | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 |
| WO2013003449A2 (en) | 2011-06-27 | 2013-01-03 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
| CA2872314C (en) | 2012-05-03 | 2021-08-31 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| SI2864350T1 (en) | 2012-06-21 | 2018-08-31 | Indiana University Research And Technology Corporation | GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR |
| ES2602486T3 (es) | 2012-06-21 | 2017-02-21 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran actividad de receptor de GIP |
| HUE035803T2 (en) | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
| DK3004155T3 (da) * | 2013-05-28 | 2022-01-03 | Takeda Pharmaceuticals Co | Peptidforbindelse |
| WO2015022420A1 (en) | 2013-08-16 | 2015-02-19 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
| CA2929459C (en) | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| AU2014345570B2 (en) | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| GB2528436A (en) | 2014-07-15 | 2016-01-27 | Lancaster Univ Business Entpr Ltd | Treatment of neurological diseases |
| WO2016034186A1 (en) | 2014-09-05 | 2016-03-10 | University Of Copenhagen | Gip peptide analogues |
| EP3212218B1 (en) | 2014-10-29 | 2021-06-30 | Zealand Pharma A/S | Gip agonist compounds and methods |
| WO2016077220A1 (en) | 2014-11-10 | 2016-05-19 | Mb2 Llc | Gip/glp-1 co-agonist peptides for human administration |
| JP2018012644A (ja) | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
| AR103242A1 (es) | 2015-01-09 | 2017-04-26 | Lilly Co Eli | Compuestos co-agonistas de gip y glp-1 |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| JP6326394B2 (ja) | 2015-10-09 | 2018-05-16 | Ｋｙｂ株式会社 | ミキサ車の積載量計量装置 |
| CN108473547A (zh) | 2015-10-28 | 2018-08-31 | 塔夫茨大学 | 具有改良的蛋白质分解安定性的新颖多肽，以及制备与使用该新颖多肽的方法 |
| JP6712323B2 (ja) | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体 |
| EP3467106B1 (en) | 2016-05-24 | 2025-07-09 | Takeda Pharmaceutical Company Limited | Peptide compound |
-
2017
- 2017-06-16 JO JOP/2019/0211A patent/JOP20190211A1/ar unknown
-
2018
- 2018-03-28 AR ARP180100762A patent/AR111346A1/es unknown
- 2018-03-29 JO JOP/2018/0028A patent/JOP20180028A1/ar unknown
- 2018-03-30 MA MA048998A patent/MA48998A/fr unknown
- 2018-03-30 MY MYPI2019005632A patent/MY205279A/en unknown
- 2018-03-30 SG SG11201908542Q patent/SG11201908542QA/en unknown
- 2018-03-30 AU AU2018246553A patent/AU2018246553B2/en active Active
- 2018-03-30 CA CA3058361A patent/CA3058361A1/en active Pending
- 2018-03-30 TW TW107111293A patent/TWI801373B/zh active
- 2018-03-30 PE PE2019001962A patent/PE20200675A1/es unknown
- 2018-03-30 EP EP18721166.9A patent/EP3601329B1/en active Active
- 2018-03-30 EA EA201992327A patent/EA201992327A1/ru unknown
- 2018-03-30 CN CN201880035168.2A patent/CN110709414B/zh active Active
- 2018-03-30 JP JP2019553587A patent/JP7175912B2/ja active Active
- 2018-03-30 US US15/941,030 patent/US10435445B2/en active Active
- 2018-03-30 BR BR112019020438A patent/BR112019020438A2/pt unknown
- 2018-03-30 IL IL269581A patent/IL269581B2/en unknown
- 2018-03-30 WO PCT/JP2018/013540 patent/WO2018181864A1/en not_active Ceased
- 2018-03-30 KR KR1020197028353A patent/KR102778100B1/ko active Active
-
2019
- 2019-08-29 US US16/555,085 patent/US11174301B2/en active Active
- 2019-09-18 ZA ZA2019/06171A patent/ZA201906171B/en unknown
- 2019-09-30 CL CL2019002790A patent/CL2019002790A1/es unknown
- 2019-09-30 PH PH12019502252A patent/PH12019502252A1/en unknown
- 2019-10-30 EC ECSENADI201978239A patent/ECSP19078239A/es unknown
- 2019-10-31 CO CONC2019/0012271A patent/CO2019012271A2/es unknown
-
2022
- 2022-02-09 AU AU2022200837A patent/AU2022200837A1/en not_active Abandoned
- 2022-11-09 JP JP2022179703A patent/JP2023012547A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019012271A2 (es) | Péptido activador de receptor de gip | |
| DOP2015000261A (es) | Compuesto peptídico como activador de los receptores del glp-1 y del gip | |
| CO2020001879A2 (es) | Compuesto heterocíclico y su uso | |
| CL2019000542A1 (es) | Compuestos de tetraciclina y métodos de uso de los mismos. | |
| CL2022000448A1 (es) | Autoinyector (divisional solicitud no. 201903061) | |
| KR102213030B9 (ko) | 신규한 보론 화합물 및 이를 포함하는 유기발광소자 | |
| MX2021016054A (es) | Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales. | |
| UY35821A (es) | Compuesto heterocíclico | |
| MX2016012530A (es) | Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso. | |
| AR094309A1 (es) | Compuesto heterociclico fusionado y uso del mismo para el control de plagas | |
| MX2020002823A (es) | Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia. | |
| MX2016006735A (es) | Dispositivo de luz. | |
| MX381970B (es) | Derivado de sulfonamida y composición farmacéutica que contiene el mismo. | |
| MX2017003476A (es) | Compuestos citotoxicos y anti-mitoticos, y metodos para usar los mismos. | |
| PY18111999A (es) | Hidroxiisoxazolinas y derivados de estos | |
| UY37153A (es) | Sulfonilamidas sustituidas para combatir parásitos animales | |
| ECSP16096831A (es) | Derivados de naftiridinadiona | |
| UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. | |
| MX394570B (es) | Complejos de clorhexidina-ciclamato y composiciones para el cuidado bucal que los comprenden | |
| CL2019000572A1 (es) | Compuesto de imida y uso del mismo. | |
| CL2017001258A1 (es) | Generación de inmunidad | |
| GT201700025S (es) | Contenedor epóxico | |
| CR20150533A (es) | Compuesto peptídico | |
| RU2013142538A (ru) | Ароматические полиэфирсульфонкетоны | |
| PY1842744A (es) | Soporte Universal Antirrobo |